Robert Temple, MD; Norman L. Stockbridge, MD, PhD
Potential Financial Conflicts of Interest: None disclosed.
Temple R., Stockbridge N.; BiDil for Heart Failure in Black Patients. Ann Intern Med. 2007;147:215-216. doi: 10.7326/0003-4819-147-3-200708070-00020
Download citation file:
Published: Ann Intern Med. 2007;147(3):215-216.
Critics of the FDA's approval of BiDil for treating heart failure in self-identified black persons have taken 2 positions: 1) Approval for blacks was premature because further testing should have been performed before approval to discover what characteristics in black and white patients might predict responses (1, 2), and 2) the FDA should have approved BiDil, but for the broader population (3). We note that Dr. Kahn, in his letter, states the latter is what he meant—not that there should have been no approval.
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only